PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii G. Bou, G. Cerveró, M.A. Domínguez, C. Quereda, J. Martínez-Beltrán Clinical Microbiology and Infection Volume 6, Issue 12, Pages 635-643 (December 2000) DOI: 10.1046/j.1469-0691.2000.00181.x Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions
Figure 1 Patterns obtained by REP-PCR. The numbers above the figure indicate the corresponding strain. Lanes III and v, DNA Molecular Weight Markers III and V, respectively (Boehringer GmbH, Mannheim, Germany). (a) IMRAB: Acinetobacter baumannii, imipenem and meropenem resistant; IMSAB: Acinetobacter baumannii, imipenem and meropenem susceptible. (b) IMSAB PRE: IMSAB strains before the outbreak (November 1996 to January 1997). IMSAB AT: IMSAB strains during the outbreak (February to July 1997). IMSAB POST: IMSAB strains after the outbreak (January to February 1998). Clinical Microbiology and Infection 2000 6, 635-643DOI: (10.1046/j.1469-0691.2000.00181.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions
Figure 2 Patterns obtained by AP-PCR. The numbers above the figure indicate the corresponding strain. Lanes III and v, DNA Molecular Weight Markers III and V, respectively (Boehringer Mannheim). (a) IMRAB: Acinetobacter baumannii, imipenem and meropenem resistant; IMSAB: Acinetobacter baumannii, imipenem and meropenem susceptible. (b) IMSAB PRE: IMSAB strains before the outbreak (November 1996 to January 1997). IMSAB AT: IMSAB strains during the outbreak (February to July 1997). IMSAB POST: IMSAB strains after the outbreak (January to February 1998). Clinical Microbiology and Infection 2000 6, 635-643DOI: (10.1046/j.1469-0691.2000.00181.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions
Figure 3 Patterns obtained by PFGE with SmaI. Lanes 1, 10, 14 and 19: Low Range PFG DNA Marker (New England Biolabs, Hitchin, Hertfordshire, UK). Lanes 2–9: IMRAB strains 1, 3, 6, 8, 24, 25, 26 and 28, respectively. Lanes 11–13: IMSAB PRE 31–33, respectively. Lanes 15–18: IMSAB AT 34–37, respectively. Lanes 20–22: IMSAB POST 38–40, respectively. Clinical Microbiology and Infection 2000 6, 635-643DOI: (10.1046/j.1469-0691.2000.00181.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions